

13<sup>th</sup> February, 2026

To,

<b>The Corporate Relationship Department</b> <b>BSE Limited</b> Phiroze Jeejeebhoy Towers, Dalal Street, Mumbai 400 001. <i>Scrip Code: 539523</i>	<b>National Stock Exchange of India Limited</b> Exchange Plaza, Bandra Kurla Complex, Bandra East, Mumbai 400 051. <i>Scrip Symbol: ALKEM</i>
---	--

**Sub: Outcome of Board Meeting held on 13<sup>th</sup> February, 2026**

Dear Sir(s)/ Madam,

This is with reference to our earlier intimation dated 23<sup>rd</sup> January, 2026, pursuant to Regulation 30 read with Regulation 33, Regulation 42 and Regulation 43 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 ("SEBI LODR Regulations"), the Board of Directors of the Company, at its meeting held today i.e. 13<sup>th</sup> February, 2026 have *inter alia*:

- a. Approved the Standalone and Consolidated Unaudited Financial Results of the Company for the quarter and nine months ended 31<sup>st</sup> December, 2025.

A copy of the said Financial Results and Limited Review Report of the Statutory Auditors of the Company, as required under Regulation 33 of the SEBI LODR Regulations, is enclosed herewith.

- b. Declared an Interim Dividend of Rs. 43/- (Rupees forty-three only) per equity share on the face value of Rs. 2/- per share for financial year 2025-2026 pursuant to Regulation 43 read with Regulation 30 of SEBI LODR Regulations.


The date of payment of Interim Dividend shall be on and from 6<sup>th</sup> March, 2026.

Further, as informed vide our letter dated 23<sup>rd</sup> January, 2026, submitted to the Stock Exchanges pursuant to Regulation 42 of SEBI LODR Regulations, the record date for the purpose of payment of Interim Dividend for financial year 2025-2026 would be Friday, 20<sup>th</sup> February, 2026.

The meeting of the Board of Directors of the Company commenced at 11:00 a.m. and concluded at 01:45 p.m.

Kindly take the same on record.

Sincerely,  
For Alkem Laboratories Limited

  
**Manish Narang**  
President - Legal, Company Secretary & Compliance Officer

Encl.: a/a

## **INDEPENDENT AUDITOR'S REVIEW REPORT ON REVIEW OF INTERIM CONSOLIDATED FINANCIAL RESULTS**

### **TO THE BOARD OF DIRECTORS OF Alkem Laboratories Limited**

1. We have reviewed the accompanying Statement of Consolidated Unaudited Financial Results of **Alkem Laboratories Limited** ("the Parent") and its subsidiaries (the Parent and its subsidiaries together referred to as "the Group"), and its share of the net loss after tax and total comprehensive income of its associate for the quarter and nine months ended December 31, 2025 ("the Statement") which includes one branch of the Group located at Nepal being submitted by the Parent pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended ("the Listing Regulations").
2. This Statement, which is the responsibility of the Parent's Management and approved by the Parent's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in the Indian Accounting Standard 34 "Interim Financial Reporting" ("Ind AS 34"), prescribed under Section 133 of the Companies Act, 2013 read with relevant rules issued thereunder and other accounting principles generally accepted in India and in compliance with Regulation 33 of the Listing Regulations. Our responsibility is to express a conclusion on the Statement based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 "Review of Interim Financial Information Performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India (ICAI). A review of interim financial information consists of making inquiries, primarily of Parent's personnel responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing specified under Section 143(10) of the Companies Act, 2013 and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

We also performed procedures in accordance with the circular issued by the SEBI under Regulation 33(8) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, to the extent applicable.

4. The Statement includes the results of the entities mentioned in Annexure I to this report.
5. Based on our review conducted and procedures performed as stated in paragraph 3 above and based on the consideration of the review reports of the other auditors referred to in paragraph 6 below, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Indian Accounting Standard and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, including the manner in which it is to be disclosed, or that it contains any material misstatement.

## **Deloitte Haskins & Sells LLP**

6. We did not review the interim financial information of four subsidiaries included in the consolidated unaudited financial results, whose interim financial information reflect total revenues of Rs. 3,120.9 million and Rs. 9,071.6 million for the quarter and nine months ended December 31, 2025 respectively, total net profit after tax of Rs. 343.6 million and Rs. 717.7 million for the quarter and nine months ended December 31, 2025 respectively and total comprehensive income of Rs. 431.4 million and Rs. 828.7 million for the quarter and nine months ended December 31, 2025 respectively, as considered in the Statement. These interim financial information have been reviewed by other auditors whose reports have been furnished to us by the Management and our conclusion on the Statement, in so far as it relates to the amounts and disclosures included in respect of these subsidiaries is based solely on the reports of the other auditors and the procedures performed by us as stated in paragraph 3 above.

Our conclusion on the Statement is not modified in respect of this matter.

7. The consolidated unaudited financial results includes the interim financial information of eighteen subsidiaries which have not been reviewed by their auditors, whose financial information reflect total revenue of Rs. 2,951.8 million and Rs. 8,269.2 million for the quarter and nine months ended December 31, 2025 respectively, total net loss after tax of Rs. 254.4 million and Rs. 119.6 million for the quarter and nine months ended December 31, 2025 respectively and total comprehensive income of Rs. (236.3) million and Rs. (70.5) million for the quarter and nine months ended December 31, 2025 respectively, as considered in the Statement. The consolidated unaudited financial results also includes the Group's share of loss after tax of Rs. 5.0 million and Rs. 14.0 million for the quarter and nine months ended December 31, 2025 respectively and total comprehensive income of Rs. (5.0) million and Rs. (14.0) million for the quarter and nine months ended December 31, 2025 respectively, as considered in the Statement, in respect of one associate, based on its interim financial information which has not been reviewed by its auditor. According to the information and explanations given to us by the Management, these interim financial information are not material to the Group.

Our Conclusion on the Statement is not modified in respect of our reliance on the interim financial information / results certified by the Management.

For **Deloitte Haskins & Sells LLP**  
Chartered Accountants  
(Firm's Registration No. 117366W/W-100018)

**Rupen K. Bhatt**  
(Partner)  
(Membership No. 046930)  
(UDIN: 26046930CFOAM12835 )

Place: Mumbai  
Date: February 13, 2026

# Deloitte Haskins & Sells LLP

## ANNEXURE I TO THE INDEPENDENT AUDITOR'S REVIEW REPORT

(Referred to in paragraph 4 under Independent Auditor's Review Report of even date)

Sr No	Name of the component	Relationship
1	Alkem Laboratories Limited	Parent
2	S&B Holdings S.a.r.l,	Wholly Owned Subsidiary
3	The Pharma Network LLC, USA (TPN)	Wholly Owned Subsidiary
4	Ascend Laboratories LLC, USA	Wholly Owned Subsidiary of TPN
5	S & B Pharma LLC	Wholly Owned Subsidiary of TPN
6	Pharmacor Pty Limited, Australia	Wholly Owned Subsidiary
7	Pharmacor SPA, Chile	Wholly Owned Subsidiary of Pharmacor Pty Limited, Australia
8	Enzene Biosciences Ltd, India	Subsidiary
9	Ascend Laboratories (PTY) Ltd, South Africa	Wholly Owned Subsidiary
10	Cachet Pharmaceuticals Pvt Ltd	Subsidiary
11	Indchemie Health Specialities Pvt Ltd, India	Subsidiary
12	Alkem Laboratories Corporation, Philippines	Wholly Owned Subsidiary
13	Ascend GmbH, Germany	Wholly Owned Subsidiary
14	Ascend Laboratories SON BHD., Malaysia	Wholly Owned Subsidiary
15	Ascend Laboratories SpA Chile (Ascend Chile)	Wholly Owned Subsidiary
16	Pharma Network SpA, Chile	Wholly Owned Subsidiary of Ascend Chile
17	Ascend Laboratories S.A. DE C.V., Mexico	Wholly Owned Subsidiary of Ascend Chile
18	Alkem Laboratories Korea Inc Korea	Wholly Owned Subsidiary
19	Pharmacor Ltd, Kenya	Wholly Owned Subsidiary
20	The Pharma Network LLP, Kazakhstan	Wholly Owned Subsidiary
21	Ascend Laboratories (UK) Ltd, UK	Wholly Owned Subsidiary
22	Ascend Laboratories Ltd, Canada	Wholly Owned Subsidiary
23	Alkem Foundation. India	Wholly Owned Subsidiary
24	Connect 2 Clinic Private Limited, India	Wholly Owned Subsidiary
25	Ascend Laboratories SAS, Colombia	Wholly Owned Subsidiary
26	Pharmacor Limited, New Zealand	Wholly Owned Subsidiary
27	Enzene Inc., USA	Wholly Owned Subsidiary of Enzene Biosciences Ltd, India
28	Alkem Medtech Private Limited, India	Wholly Owned Subsidiary
29	Alixer Nexgen Therapeutics Limited	Wholly Owned Subsidiary
30	Alkem Wellness Limited	Wholly Owned Subsidiary
31	Adroit Biomed Limited	Wholly Owned Subsidiary
32	Alkem Medtech Ortho Private Limited (formerly known as Bombay Ortho Industries Private Limited)	Wholly Owned Subsidiary of Alkem Medtech Private Limited, India
33	Haystack Analytics Private Limited	Associate

R  
D

# ALKEM LABORATORIES LIMITED

CIN No.:L00305MH1973PLC174201

Regd. Office and Corporate Office: Alkem House, Senapati Bapat Marg, Lower Parel, Mumbai - 400013, Maharashtra, India.

Tel No:91 22 3982 9999 Fax No: +91 22 2492 7190

Website : www.alkemlabs.com, Email Id : investors@alkem.com

## Statement of Consolidated Financial Results for the Quarter and Nine months ended 31 December 2025

(₹ in Million except per share data)

	Particulars	Quarter ended			Nine months ended		Year ended
		31.12.2025 Unaudited	30.09.2025 Unaudited	31.12.2024 Unaudited	31.12.2025 Unaudited	31.12.2024 Unaudited	31.03.2025 (Audited)
<b>1</b>	<b>Income</b>						
	(a) Revenue from Operations	37,368.2	40,009.9	33,742.8	111,089.5	98,207.7	129,645.2
	(b) Other Income	1,431.0	1,036.9	929.9	3,832.8	3,477.8	4,937.4
	<b>Total Income</b>	<b>38,799.2</b>	<b>41,046.8</b>	<b>34,672.7</b>	<b>114,922.3</b>	<b>101,685.5</b>	<b>134,582.6</b>
<b>2</b>	<b>Expenses</b>						
	(a) Cost of materials consumed	9,377.7	9,055.7	9,240.1	26,704.5	26,633.4	34,403.7
	(b) Purchases of stock-in-trade	3,279.6	4,715.7	3,974.8	11,967.3	11,340.6	15,140.2
	(c) Changes in inventories of finished goods, work-in-progress and stock-in-trade	69.8	238.9	(1,171.6)	(222.8)	(3,124.2)	(1,901.3)
	(d) Employee benefits expense	7,215.1	7,102.5	6,248.1	21,250.1	18,375.7	24,539.2
	(e) Finance costs	421.0	350.2	360.3	1,069.0	932.8	1,217.0
	(f) Depreciation and amortisation expense	950.1	936.1	852.8	2,763.0	2,446.7	3,571.6
	(g) Other expenses	9,146.0	9,689.4	7,857.5	26,512.2	23,773.6	32,341.9
	<b>Total Expenses</b>	<b>30,459.3</b>	<b>32,088.5</b>	<b>27,362.0</b>	<b>90,043.3</b>	<b>80,378.6</b>	<b>109,312.3</b>
<b>3</b>	<b>Profit before exceptional items and tax (1) - (2)</b>	<b>8,339.9</b>	<b>8,958.3</b>	<b>7,310.7</b>	<b>24,879.0</b>	<b>21,306.9</b>	<b>25,270.3</b>
<b>4</b>	<b>Exceptional items (refer note 3)</b>	<b>(527.9)</b>	<b>-</b>	<b>-</b>	<b>(398.6)</b>	<b>-</b>	<b>-</b>
<b>5</b>	<b>Profit before tax (3) + (4)</b>	<b>7,812.0</b>	<b>8,958.3</b>	<b>7,310.7</b>	<b>24,480.4</b>	<b>21,306.9</b>	<b>25,270.3</b>
<b>6</b>	<b>Tax expense / (credit)</b>						
	(a) Current tax	1,769.7	1,799.5	1,590.4	4,980.3	4,393.5	5,236.0
	(b) Deferred tax	(493.0)	(637.2)	(687.6)	(1,514.4)	(2,016.5)	(2,125.7)
	<b>Total Tax Expense (a + b)</b>	<b>1,276.7</b>	<b>1,162.3</b>	<b>902.8</b>	<b>3,465.9</b>	<b>2,377.0</b>	<b>3,110.3</b>
<b>7</b>	<b>Share in loss after tax of associate</b>	<b>(5.0)</b>	<b>(4.9)</b>	<b>-</b>	<b>(14.0)</b>	<b>-</b>	<b>(6.2)</b>
<b>8</b>	<b>Profit for the period (5) - (6) + (7)</b>	<b>6,530.3</b>	<b>7,791.1</b>	<b>6,407.9</b>	<b>21,000.5</b>	<b>18,929.9</b>	<b>22,153.8</b>
<b>9</b>	<b>Other Comprehensive Income (net of tax)</b>						
	(a) (i) Items that will not be reclassified to profit or loss	(141.2)	(44.9)	(37.6)	(233.7)	(153.8)	(218.1)
	(ii) Income tax relating to items that will not be reclassified to profit or loss	50.8	26.6	13.0	80.3	50.4	72.1
	(b) (i) Items that will be reclassified to profit or loss	326.1	447.0	145.6	838.6	326.5	343.2
	(ii) Income tax relating to items that will be reclassified to profit or loss	-	-	-	-	-	-
	<b>Total Other Comprehensive Income (net of tax)</b>	<b>235.7</b>	<b>428.7</b>	<b>121.0</b>	<b>685.2</b>	<b>223.1</b>	<b>197.2</b>
<b>10</b>	<b>Total Comprehensive Income for the period (8) + (9)</b>	<b>6,766.0</b>	<b>8,219.8</b>	<b>6,528.9</b>	<b>21,685.7</b>	<b>19,153.0</b>	<b>22,351.0</b>
<b>11</b>	<b>Profit attributable to</b>						
	a) Owners of the Company	6,360.2	7,650.6	6,258.2	20,653.4	18,596.2	21,654.8
	b) Non-Controlling Interest	170.1	140.5	149.7	347.1	333.7	499.0
<b>12</b>	<b>Other Comprehensive Income attributable to</b>						
	a) Owners of the Company	235.2	432.4	120.7	690.7	233.3	207.5
	b) Non-Controlling Interest	0.5	(3.7)	0.3	(5.5)	(10.2)	(10.3)
<b>13</b>	<b>Total Comprehensive Income attributable to</b>						
	a) Owners of the Company	6,595.4	8,083.0	6,378.9	21,344.1	18,829.5	21,862.3
	b) Non-Controlling Interest	170.6	136.8	150.0	341.6	323.5	488.7
<b>14</b>	<b>Paid-up Equity Share Capital</b> (Face Value ₹ 2 each fully paid up)	<b>239.1</b>	<b>239.1</b>	<b>239.1</b>	<b>239.1</b>	<b>239.1</b>	<b>239.1</b>
<b>15</b>	<b>Other Equity</b>						<b>119,609.6</b>
<b>16</b>	<b>Earnings Per Share (not annualised for the periods) (face value of ₹ 2/- each)</b>						
	(a) Basic (₹)	53.19	63.99	52.34	172.74	155.54	181.11
	(b) Diluted (₹)	53.19	63.99	52.34	172.74	155.54	181.11


**Notes to the Consolidated Financial results:**

- 1 The above consolidated financial results are prepared in accordance with the Indian Accounting Standards prescribed under section 133 of the Companies Act, 2013 and are in compliance with the presentation and disclosure requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended).
- 2 The above consolidated financial results of the Group were reviewed and recommended by the Audit Committee on 12 February 2026 and subsequently approved by the Board of Directors at its meeting held on 13 February 2026. The auditors have issued an unmodified review report on the financial results for the quarter and nine months ended 31 December 2025.
- 3 Exceptional items include:
  - a) The Government of India notified the four Labour Codes which are effective from November 21, 2025. The Ministry of Labour & Employment published draft Central Rules and FAQs to enable assessment of the financial impact due to changes in regulations. The Group has assessed the incremental impact of these changes on the basis of the best information available, consistent with the guidance provided by the Institute of Chartered Accountants of India.

The incremental impact basis preliminary analysis of ₹527.9 million is classified and disclosed as an exceptional item in the results for the quarter and nine months ended 31 December 2025. The Group continues to monitor the finalisation of Central/ State Rules and clarifications from the Government on other aspects of the Labour Code and would provide appropriate financial impact on the basis of such developments as needed.
  - b) The Parent Company sold its Indore manufacturing facility in the quarter ended 30 June 2025 in accordance with the business transfer agreement entered with the buyer. The resulting gain amounting to ₹142.9 million had been classified and disclosed as an exceptional item in the results for the nine months ended 31 December 2025.
- 4 The Board of Directors at its meeting held on 13 February 2026 have declared an interim dividend of ₹ 43 (Rupees Forty Three only) per equity share (2150% on the face value of ₹ 2 each) for the financial year ending 31 March 2026.
- 5 The Group operates in one reportable business segment i.e. "Pharmaceuticals", accordingly no separate disclosure of segment information has been made.



By Order of the Board  
For Alkem Laboratories Limited



**B.N. Singh**  
Executive Chairman  
DIN: 00760310

Place: Mumbai  
Date: 13 February 2026

## INDEPENDENT AUDITOR'S REVIEW REPORT ON REVIEW OF INTERIM STANDALONE FINANCIAL RESULTS

### TO THE BOARD OF DIRECTORS OF Alkem Laboratories Limited

1. We have reviewed the accompanying Statement of Standalone Unaudited Financial Results of **Alkem Laboratories Limited** ("the Company"), which includes a branch located at Nepal, for the quarter and nine months ended December 31, 2025, ("the Statement"), being submitted by the Company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended ("the Listing Regulations").
2. This Statement, which is the responsibility of the Company's Management and approved by the Company's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in the Indian Accounting Standard 34 "Interim Financial Reporting" ("Ind AS 34"), prescribed under Section 133 of the Companies Act, 2013 read with relevant rules issued thereunder and other accounting principles generally accepted in India and in compliance with Regulation 33 of the Listing Regulations. Our responsibility is to express a conclusion on the Statement based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 'Review of Interim Financial Information Performed by the Independent Auditor of the Entity', issued by the Institute of Chartered Accountants of India (ICAI). A review of interim financial information consists of making inquiries, primarily of the Company's personnel responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing specified under section 143(10) of the Companies Act, 2013 and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.
4. Based on our review conducted as stated in paragraph 3 above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Indian Accounting Standard and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, including the manner in which it is to be disclosed, or that it contains any material misstatement.

For **Deloitte Haskins & Sells LLP**  
Chartered Accountants  
(Firm's Registration No. 117366W/W-100018)



**Rupen K. Bhatt**  
(Partner)  
(Membership No. 046930)  
(UDIN:26046930PMYHKL6517 )



Place: Mumbai  
Date: February 13, 2026

ALKEM LABORATORIES LIMITED

CIN No.:L00305MH1973PLC174201

Regd. Office and Corporate Office: Alkem House, Senapati Bapat Marg, Lower Parel, Mumbai - 400013, Maharashtra, India.

Tel No:91 22 3982 9999 Fax No: +91 22 2492 7190

Website : www.alkemlabs.com, Email Id : investors@alkem.com

Statement of Standalone Financial Results for the Quarter and Nine months ended 31 December 2025

(₹ in Million except per share data)

	Particulars	Quarter ended			Nine months ended		Year ended
		31.12.2025 (Unaudited)	30.09.2025 (Unaudited)	31.12.2024 (Unaudited)	31.12.2025 (Unaudited)	31.12.2024 (Unaudited)	31.03.2025 (Audited)
<b>1</b>	<b>Continuing Operations</b>						
	<b>Income</b>						
	(a) Revenue from Operations	24,912.7	25,420.3	22,868.3	74,054.7	67,685.0	88,134.4
	(b) Other Income	1,315.3	1,013.7	1,691.8	3,494.8	3,954.7	5,070.6
	<b>Total Income</b>	<b>26,228.0</b>	<b>26,434.0</b>	<b>24,560.1</b>	<b>77,549.5</b>	<b>71,639.7</b>	<b>93,205.0</b>
<b>2</b>	<b>Expenses</b>						
	(a) Cost of materials consumed	5,875.1	5,676.3	6,931.3	17,704.7	19,445.1	23,959.2
	(b) Purchases of stock-in-trade	1,131.0	1,228.4	1,209.0	3,194.5	3,043.7	3,896.1
	(c) Changes in inventories of finished goods, work-in-progress and stock-in-trade	156.7	(26.0)	(881.5)	210.0	(1,305.3)	566.1
	(d) Employee benefits expense	4,855.8	4,608.5	4,184.8	14,161.7	12,293.3	16,309.6
	(e) Finance costs	155.1	127.5	210.0	410.5	592.0	761.1
	(f) Depreciation and amortisation expenses	609.1	585.9	676.1	1,783.9	1,919.7	2,836.1
	(g) Other expenses	6,002.0	6,226.3	4,846.4	17,980.1	15,614.1	21,841.4
	<b>Total Expenses</b>	<b>18,784.8</b>	<b>18,426.9</b>	<b>17,176.1</b>	<b>55,445.4</b>	<b>51,602.6</b>	<b>70,169.6</b>
<b>3</b>	<b>Profit before exceptional items and tax from continuing operations (1) - (2)</b>	<b>7,443.2</b>	<b>8,007.1</b>	<b>7,384.0</b>	<b>22,104.1</b>	<b>20,037.1</b>	<b>23,035.4</b>
<b>4</b>	<b>Exceptional items (Refer note 4)</b>	<b>(381.7)</b>	<b>-</b>	<b>-</b>	<b>(238.8)</b>	<b>-</b>	<b>-</b>
<b>5</b>	<b>Profit before tax from continuing operations (3) + (4)</b>	<b>7,061.5</b>	<b>8,007.1</b>	<b>7,384.0</b>	<b>21,865.3</b>	<b>20,037.1</b>	<b>23,035.4</b>
<b>6</b>	<b>Tax expense / (credit)</b>						
	(a) Current tax	1,243.9	1,235.6	1,198.8	3,572.9	3,133.8	3,501.3
	(b) Deferred tax	(403.8)	(465.1)	(577.1)	(1,388.2)	(1,735.1)	(1,363.1)
	<b>Total Tax expense (a + b)</b>	<b>840.1</b>	<b>770.5</b>	<b>621.7</b>	<b>2,184.7</b>	<b>1,398.7</b>	<b>2,138.2</b>
<b>7</b>	<b>Profit for the period after tax from continuing operations (5 - 6)</b>	<b>6,221.4</b>	<b>7,236.6</b>	<b>6,762.3</b>	<b>19,680.6</b>	<b>18,638.4</b>	<b>20,897.2</b>
	<b>Discontinued operations (Refer note 3)</b>						
	Profit before tax from discontinued operations	-	969.5	720.7	1,490.5	2,153.7	2,938.5
	Tax expense of discontinued operations	-	338.8	251.8	520.8	752.6	1,026.8
<b>8</b>	<b>Profit from discontinued operations (after tax)</b>	<b>-</b>	<b>630.7</b>	<b>468.9</b>	<b>969.7</b>	<b>1,401.1</b>	<b>1,911.7</b>
<b>9</b>	<b>Profit for the period (7) + (8)</b>	<b>6,221.4</b>	<b>7,867.3</b>	<b>7,231.2</b>	<b>20,650.3</b>	<b>20,039.5</b>	<b>22,808.9</b>
<b>10</b>	<b>Other Comprehensive Income (net of tax)</b>						
	<b>I. In respect of continuing operations:</b>						
	(a) (i) Items that will not be reclassified to profit or loss	(147.0)	(31.3)	(39.9)	(209.7)	(119.5)	(170.3)
	(ii) Income tax relating to items that will not be reclassified to profit or loss	51.3	11.0	14.0	73.3	41.8	59.5
	(b) (i) Items that will be reclassified to profit or loss	-	-	-	-	-	-
	(ii) Income tax relating to items that will be reclassified to profit or loss	-	-	-	-	-	-
	<b>II. In respect of discontinued operations:</b>						
	(a) (i) Items that will not be reclassified to profit or loss	-	(1.9)	1.6	(3.6)	4.7	(6.5)
	(ii) Income tax relating to items that will not be reclassified to profit or loss	-	0.6	(0.6)	1.2	(1.7)	2.3
	(b) (i) Items that will be reclassified to profit or loss	-	-	-	-	-	-
	(ii) Income tax relating to items that will be reclassified to profit or loss	-	-	-	-	-	-
	<b>Total Other Comprehensive Income (net of tax)</b>	<b>(95.7)</b>	<b>(21.6)</b>	<b>(24.9)</b>	<b>(138.8)</b>	<b>(74.7)</b>	<b>(115.0)</b>
<b>11</b>	<b>Total Comprehensive Income for the period (9) + (10)</b>	<b>6,125.7</b>	<b>7,845.7</b>	<b>7,206.3</b>	<b>20,511.5</b>	<b>19,964.8</b>	<b>22,693.9</b>
<b>12</b>	<b>Paid-up Equity Share Capital</b> (Face Value ₹ 2 each fully paid up)	<b>239.1</b>	<b>239.1</b>	<b>239.1</b>	<b>239.1</b>	<b>239.1</b>	<b>239.1</b>
<b>13</b>	<b>Other Equity</b>						<b>122,979.2</b>
<b>14</b>	<b>Earnings Per Share (not annualised for the periods) (for continuing operations) (face value of ₹ 2/- each)</b>						
	(a) Basic (₹)	52.03	60.53	56.56	164.60	155.89	174.78
	(b) Diluted (₹)	52.03	60.53	56.56	164.60	155.89	174.78
	<b>Earnings Per Share (not annualised for the periods) (for discontinued operations) (face value of ₹ 2/- each)</b>						
	(a) Basic (₹)	-	5.27	3.92	8.11	11.71	15.99
	(b) Diluted (₹)	-	5.27	3.92	8.11	11.71	15.99
	<b>Earnings Per Share (not annualised for the periods) (from total operations) (face value of ₹ 2/- each)</b>						
	(a) Basic (₹)	52.03	65.80	60.48	172.71	167.60	190.77
	(b) Diluted (₹)	52.03	65.80	60.48	172.71	167.60	190.77

**Notes to the Standalone Financial results:**

- 1 The above standalone financial results are prepared in accordance with the Indian Accounting Standards prescribed under section 133 of the Companies Act, 2013 and are in compliance with the presentation and disclosure requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended).
- 2 The above standalone financial results of the Company were reviewed and recommended by the Audit Committee on 12 February 2026 and subsequently approved by the Board of Directors at its meeting held on 13 February 2026. The auditors have issued an unmodified review report on the financial results for the quarter and nine months ended 31 December 2025.
- 3 The Board of Directors of the Company at their meeting held on 10 December 2024 had approved the transfer of Generic Business Undertaking to Alkem Wellness Limited, a wholly owned subsidiary of the Company as a going concern, on a slump sale basis. The Company has executed a Business Transfer Agreement (BTA), effective 01 October 2025, and transferred its Generic business to Alkem Wellness Limited.

During the earlier periods, the proposed transfer of the Generic Business has been disclosed as discontinued operations in accordance with Ind AS 105 "Non - current Assets Held for Sale and Discontinued Operations". The figures for the previous periods have been restated to give effect to the presentation requirement of Ind AS 105 "Non - current Assets Held for Sale and Discontinued Operations".

**Key financial information of Discontinued Operations:**

Particulars	Quarter ended			Nine months ended		Year ended
	31.12.2025	30.09.2025	31.12.2024	31.12.2025*	31.12.2024	31.03.2025
Total income	-	5,622.8	4,880.4	9,181.0	13,784.4	18,974.9
Total expenses	-	4,653.3	4,159.7	7,690.5	11,630.7	16,036.4
Profit before tax	-	969.5	720.7	1,490.5	2,153.7	2,938.5
Total tax expense	-	338.8	251.8	520.8	752.6	1,026.8
Net profit for the period after tax	-	630.7	468.9	969.7	1,401.1	1,911.7

\*Note: The figures for the nine months ended 31 December 2025 are not comparable with those of the corresponding period, as they reflect carved-out results up to 30 September 2025, the date on which the generic business was transferred to Alkem Wellness Limited.

- 4 Exceptional items include:


a) The Government of India notified the four Labour Codes which are effective from November 21, 2025. The Ministry of Labour & Employment published draft Central Rules and FAQs to enable assessment of the financial impact due to changes in regulations. The Company has assessed the incremental impact of these changes on the basis of the best information available, consistent with the guidance provided by the Institute of Chartered Accountants of India.

The incremental impact basis preliminary analysis of ₹ 381.7 million is classified and disclosed as an exceptional item in the results for the quarter and nine months ended 31 December 2025. The Company continues to monitor the finalisation of Central/ State Rules and clarifications from the Government on other aspects of the Labour Code and would provide appropriate financial impact on the basis of such developments as needed.

b) The Company as part of its ongoing initiative of networking, strategy and optimisation of manufacturing facilities had identified divestment of its Indore facility. The said facility had been sold in the quarter ended 30 June 2025 in accordance with the business transfer agreement entered with the buyer. The resulting gain amounting to ₹142.9 million had been classified and disclosed as an exceptional item in the results for the nine months ended 31 December 2025.

- 5 The Board of Directors at its meeting held on 13 February 2026 have declared an interim dividend of ₹ 43 (Rupees Forty Three only) per equity share (2150 % on the face value of ₹ 2 each) for the financial year ending 31 March 2026.
- 6 The Company operates in one reportable business segment i.e. "Pharmaceuticals", accordingly no separate disclosure of segment information has been made.

By Order of the Board  
For Alkem Laboratories Limited



**B.N. Singh**  
Executive Chairman  
DIN: 00760310

Place: Mumbai  
Date: 13 February 2026